PL3411021T3 - Nowe zastosowanie kombinacji sakubitrylu i walsartanu - Google Patents
Nowe zastosowanie kombinacji sakubitrylu i walsartanuInfo
- Publication number
- PL3411021T3 PL3411021T3 PL17703477.4T PL17703477T PL3411021T3 PL 3411021 T3 PL3411021 T3 PL 3411021T3 PL 17703477 T PL17703477 T PL 17703477T PL 3411021 T3 PL3411021 T3 PL 3411021T3
- Authority
- PL
- Poland
- Prior art keywords
- sacubitril
- new application
- valsartan
- combination
- valsartan combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16154153 | 2016-02-03 | ||
| US201662293005P | 2016-02-09 | 2016-02-09 | |
| US201662393163P | 2016-09-12 | 2016-09-12 | |
| PCT/IB2017/050573 WO2017134600A1 (en) | 2016-02-03 | 2017-02-02 | New use of a combination of sacubitril and valsartan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3411021T3 true PL3411021T3 (pl) | 2025-09-08 |
Family
ID=55299378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17703477.4T PL3411021T3 (pl) | 2016-02-03 | 2017-02-02 | Nowe zastosowanie kombinacji sakubitrylu i walsartanu |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20190054069A1 (pl) |
| EP (3) | EP4609912A3 (pl) |
| JP (4) | JP7156945B2 (pl) |
| KR (1) | KR102805176B1 (pl) |
| CN (1) | CN108601741B (pl) |
| AU (2) | AU2017215530B2 (pl) |
| CA (1) | CA3010778C (pl) |
| DK (1) | DK3411021T3 (pl) |
| ES (1) | ES3036922T3 (pl) |
| FI (1) | FI3411021T3 (pl) |
| HR (1) | HRP20250913T1 (pl) |
| HU (1) | HUE072182T2 (pl) |
| IL (1) | IL260955A (pl) |
| LT (1) | LT3411021T (pl) |
| PL (1) | PL3411021T3 (pl) |
| PT (1) | PT3411021T (pl) |
| RS (1) | RS67127B1 (pl) |
| SI (1) | SI3411021T1 (pl) |
| WO (2) | WO2017134597A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017134597A1 (en) | 2016-02-03 | 2017-08-10 | Novartis Ag | Galenic formulations of organic compounds |
| EP3694493A1 (en) * | 2017-10-13 | 2020-08-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Tablet containing valsartan and sacubitril |
| KR20210032437A (ko) * | 2018-08-23 | 2021-03-24 | 노파르티스 아게 | 심부전의 치료를 위한 신규한 약제학적 용도 |
| WO2021172960A1 (ko) * | 2020-02-26 | 2021-09-02 | 에리슨제약(주) | 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법 |
| KR102545274B1 (ko) * | 2020-02-26 | 2023-06-20 | 에리슨제약(주) | 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법 |
| CN116887866A (zh) | 2020-12-03 | 2023-10-13 | 巴特尔纪念研究院 | 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法 |
| KR20220091767A (ko) * | 2020-12-24 | 2022-07-01 | 주식회사 보령 | 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물 |
| JP2024516108A (ja) | 2021-04-07 | 2024-04-12 | バテル・メモリアル・インスティテュート | 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術 |
| US20240307352A1 (en) * | 2021-07-12 | 2024-09-19 | Shanghai Aurora Biotechnology Co., Ltd. | Sacubitril valsartan sodium sustained-release composition, and preparation method therefor and use thereof |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59107440D1 (de) | 1990-02-19 | 1996-04-04 | Ciba Geigy Ag | Acylverbindungen |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| HUP0401941A3 (en) * | 2001-07-16 | 2008-04-28 | Astrazeneca Ab | Pharmaceutical formulation comprising a proton pomp inhibitor and antacids and process for its preparation |
| KR20100057704A (ko) | 2002-01-17 | 2010-05-31 | 노파르티스 아게 | 발사르탄 및 nep 저해제를 포함하는 제약학적 조성물 |
| US7638638B2 (en) * | 2003-05-14 | 2009-12-29 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| MX2010004930A (es) * | 2007-11-06 | 2010-05-27 | Novartis Ag | Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep). |
| TWI468191B (zh) * | 2009-01-28 | 2015-01-11 | Novartis Ag | 有機化合物之調配物 |
| CN103079554A (zh) | 2010-08-24 | 2013-05-01 | 诺华有限公司 | 在接受抗凝血剂疗法的哺乳动物中治疗高血压和/或预防或治疗心力衰竭 |
| CA2882771C (en) | 2012-08-24 | 2021-02-23 | Novartis Ag | Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling |
| WO2015030711A1 (en) | 2013-08-26 | 2015-03-05 | Novartis Ag | New use |
| RS59816B1 (sr) | 2013-08-26 | 2020-02-28 | Novartis Ag | Nova primena |
| WO2017134597A1 (en) | 2016-02-03 | 2017-08-10 | Novartis Ag | Galenic formulations of organic compounds |
-
2017
- 2017-02-02 WO PCT/IB2017/050569 patent/WO2017134597A1/en not_active Ceased
- 2017-02-02 JP JP2018540446A patent/JP7156945B2/ja active Active
- 2017-02-02 US US16/074,589 patent/US20190054069A1/en not_active Abandoned
- 2017-02-02 PT PT177034774T patent/PT3411021T/pt unknown
- 2017-02-02 CN CN201780009566.2A patent/CN108601741B/zh active Active
- 2017-02-02 LT LTEPPCT/IB2017/050573T patent/LT3411021T/lt unknown
- 2017-02-02 EP EP25175340.6A patent/EP4609912A3/en active Pending
- 2017-02-02 EP EP17703476.6A patent/EP3411018A1/en active Pending
- 2017-02-02 ES ES17703477T patent/ES3036922T3/es active Active
- 2017-02-02 SI SI201731616T patent/SI3411021T1/sl unknown
- 2017-02-02 AU AU2017215530A patent/AU2017215530B2/en active Active
- 2017-02-02 WO PCT/IB2017/050573 patent/WO2017134600A1/en not_active Ceased
- 2017-02-02 HU HUE17703477A patent/HUE072182T2/hu unknown
- 2017-02-02 KR KR1020187022178A patent/KR102805176B1/ko active Active
- 2017-02-02 DK DK17703477.4T patent/DK3411021T3/da active
- 2017-02-02 EP EP17703477.4A patent/EP3411021B1/en active Active
- 2017-02-02 JP JP2018540466A patent/JP6810152B2/ja active Active
- 2017-02-02 RS RS20250742A patent/RS67127B1/sr unknown
- 2017-02-02 FI FIEP17703477.4T patent/FI3411021T3/fi active
- 2017-02-02 CA CA3010778A patent/CA3010778C/en active Active
- 2017-02-02 HR HRP20250913TT patent/HRP20250913T1/hr unknown
- 2017-02-02 PL PL17703477.4T patent/PL3411021T3/pl unknown
-
2018
- 2018-08-02 IL IL260955A patent/IL260955A/en unknown
-
2019
- 2019-12-12 AU AU2019280026A patent/AU2019280026B2/en active Active
-
2022
- 2022-10-28 JP JP2022173240A patent/JP2023021991A/ja not_active Withdrawn
-
2023
- 2023-08-03 US US18/364,880 patent/US20240207227A1/en not_active Abandoned
-
2024
- 2024-08-23 JP JP2024141820A patent/JP2024160386A/ja active Pending
- 2024-12-05 US US18/970,329 patent/US20250325518A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20230014I1 (fi) | Foslevodopa ja foskarbidopa | |
| IL293377A (en) | Hsd17b13 variants and uses thereof | |
| IL259441A (en) | Materials and methods for treatment of titin-based myopathies and other titinopaties | |
| IL282048A (en) | Oxysterols and methods of use thereof | |
| EP4212536C0 (en) | BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | |
| PT3548033T (pt) | Compostos e respectivos métodos de utilização | |
| IL263680A (en) | Combination therapies | |
| PT3368534T (pt) | Ditosilato de valbenazina e polimorfos do mesmo | |
| IL252026B (en) | Humanized anti-complement factor c1q antibodies and uses thereof | |
| PL3353210T3 (pl) | Przeciwciała anty-TIGIT i sposoby stosowania | |
| IL280863A (en) | Autotaxin inhibitors and uses thereof | |
| IL251970B (en) | Anti-cd79b antibodies and methods of use | |
| PL3411021T3 (pl) | Nowe zastosowanie kombinacji sakubitrylu i walsartanu | |
| BR112018000129A2 (pt) | oxiesteróis e seus métodos de utilização | |
| HUE046000T2 (hu) | Antiproferatív vegyületek és alkalmazásuk módszerei | |
| EP3411412A4 (en) | FIT-IMMUNOGLOBULIN TECHNOLOGY AND USES THEREOF | |
| HUE052373T2 (hu) | Szubsztituált krománok és alkalmazási eljárások | |
| PL3265448T3 (pl) | Proleki riluzolu i ich zastosowanie | |
| MA41997A (fr) | Combinaisons de cannabinoïdes et de n-acyléthanolamines | |
| KR102068915B9 (ko) | 조직 인자 경로 억제제 항체 및 그의 용도 | |
| DK3182962T3 (da) | Compositions and uses of amidine derivatives | |
| BR112016020889A2 (pt) | variantes de hppd e métodos de uso | |
| EP3481952A4 (en) | METHYLATION MARKERS IN THE TREATMENT OF LEUKEMIA AND USES THEREOF | |
| IL250173B (en) | Actuation mechanism and associated methods | |
| DK3194564T3 (da) | Trichodermasammensætninger og anvendelsesfremgangsmåder |